Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with milnacipran (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with milnacipran (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
Paroxetine probably leads to higher failure to respond at 1‐4 weeks compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine probably leads to higher failure to remit at endpoint compared with mirtazapine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with nefazodone (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with reboxetine (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in clinical global assessment scale scores (CGI scale or CGAS rated between 4 and 10 weeks of onset of treatment) · children and adolescents with depression
1 finding from 1 review
Intervention not reported
Number of withdrawals (occurring between 4 and 10 weeks of onset of treatment) · children and adolescents with depression
The intervention showed no clear difference in number of withdrawals (occurring between 4 and 10 weeks of onset of… (low certainty).
1 finding from 1 review